Back to MphaR main website
Virtual Platform Website
Request Demo Version
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Trends in Pharma

The Future of Pharma: Top 5 trends impacting the pharmaceutical industry in 2023

Written by Natalia Denisova, PhD VP, Head of Medical Affairs MphaR
September 11, 2023

It's safe to say that the COVID-19 outbreak was a powerful catalyst for the recent advancements and evolution of the pharma industry. There are a slew of interesting trends that we'll be seeing towards the end of 2023. The scientific advancements and the rapid implementation of medical technologies and digitalization are a testament to the fact that modern pharmaceutical industries will remain steadfast in their strife to continually manufacture innovative and future-proof medical solutions as well as products, leaning completely towards offering streamlined and advanced patient care. 

For instance, cutting-edge virtual technologies and platforms have positively modified patient experience. On the other hand, the medical industry has also rapidly adopted remote working trends, continuously leveraging the power and effectiveness of virtual training and tools. While it's true that major pharmaceutical companies are often bashed for their profiteering strategies, it's unjustified to deny the many developmental contributions and medical breakthroughs they have made regarding both patient care and overall public health. The industry is on a constant path to innovation, continually adopting tech-based novel strategies for not just creating lifesaving drugs but also providing education to HCPs worldwide, which plays a vital role in enhancing patient outcomes.  

In light of this, we're going to take a comprehensive dice into understanding some powerful and cutting-edge trends that will undoubtedly shape the future of medicine and global healthcare in 2023 and beyond. 

Rampant Use of Artificial Intelligence and Machine Learning

Pharmaceutical companies are gradually unveiling how they're combining the use of both artificial intelligence and machine learning, using groundbreaking methodologies in disease imaging and telemedicine, providing medical professionals with cutting-edge tools and research needed to treat debilitating and terminal diseases such as blood cancer, internal bleeding, and diabetic retinopathy. Plus, modern pharma companies have incessantly begun to incorporate AI tools and platforms to assist HCPs in streamlining patient consultations in the form of voice-activated AI medical assistants that help efficiently transcribe notes and procedural instructions. 

Medical innovators and manufacturers believe that AI could offer limitless opportunities and possibilities to make modern healthcare infinitely more effective and accessible. This is primarily why mainstream pharma companies are seen harnessing the power of advanced data analytics and machine learning to extract a staggering volume of real-world clinical data and research. This allows them to offer precision-based disease diagnosis and patient consultation, HCPs to administer customized treatment plans, design effective patient trials, and continuously streamline the viability of medical affairs strategies. 

On the other hand, machine learning platforms have also exponentially optimized the capabilities of HCPs and medical manufacturers. How? Well, the recent COVID-19 pandemic exponentially propelled the need for AI-powered software and platforms that could replace human employees with robots, or you could say, mechanical machines that solely functioned on the concept of machine learning. These platforms can constantly learn from experience and continually perform with optimum efficiency without needing to be frequently or specifically programmed. 

The use of machine learning in modern medical manufacturing companies and pharmaceuticals essentially focuses on optimizing core medical proficiencies with the use of artificial intelligence. It is not being used to replace the experience, foresight, and knowledge of a human doctor. By blending the knowledge and experience of HCPs, physicians, and surgeons with machine learning, artificial intelligence, and big data analytics, medical manufacturers have increasingly been able to develop new techniques and strategies for disease identification and diagnosis, creation of new drugs, effective medical interventions, and streamlined patient care and outcomes. Machine learning can offer comprehensive insight into accurate patient consultation, and diagnoses, and offer HCPs better treatment options. Today, doctors can be seen using both AI and machine learning platforms in X-ray and CT scan reading, allowing them to disqualify anomalies and determine complex nodules and precursors in patients suffering from lung cancer. 

Virtual Advisory Boards 

Virtual advisory boards offer pharma companies and medical professionals a high degree of communication flexibility and unmatched accessibility. Virtual advisory boards provide a slew of excellent features such as document tracking, seamless communications, online voting, etc. In addition, participants such as key opinion leaders (KOLs), medical professionals, and industry leaders get to engage in conferences and meetings in a way that suits their schedule whether the engagement is in the form of written comments, podcasts, audio recordings, etc.  

Moreover, a digital format also enables a ton of modifications to be implemented without wasting any time. This is an excellent advantage compared to physical conferences where the engagement was always restricted to specific schedules and locations. But perhaps one of the greatest benefits of virtual advisory boards is their sheer capability for scalability. You see, because the participants aren't geographically constrained and because it's a digital platform, the event can be scaled to accommodate an unlimited amount of people. With guaranteed accessibility and flexibility, virtual platforms make it extremely easy for pharmaceutical and medical professionals to dynamically adapt to changing trends, making sure everything is in line with requirements specified by pharma advisors, KOLs, company leaders, etc. 

In addition, virtual advisory boards also help pharmaceutical companies, KOLs, and HCPs to considerably optimize the level of reach. Because geography is no longer a concern, key participants have the power to use VABs to reach, consult, and interview thought leaders, important stakeholders, and HCPs no matter where they are in the world. This level of global reach doesn't just help pharma companies and medical professionals to diversify the insights gathered but it also helps cement the trust levels amongst KOLs and medical professionals from across the world. 

Patient-Oriented Methodologies and RWE-Based Outcomes  

The relevancy and viability of real-world evidence in decision-making are rapidly gaining traction. Pharmaceutical companies are seen implementing real-world disease and treatment methodologies and research to acquire global market access, develop better regulatory measures, and effectively demonstrate the benefits and value of their products to stakeholders, medical professionals, and patients. This trend is what is allowing global medical affairs teams to implement effective strategies to quickly develop and gather real-world evidence outcomes for better and faster clinical care. 

Moreover, there's also an inclination towards developing a more patient-oriented approach seen in the modern pharma industry. Medical affairs teams are constantly communicating with patients to precisely understand what they expect in terms of patient care and treatment as well as voice their preferences. 

Enhanced Digitalization 

Digitalization is amongst the most prevailing trends in the pharma industry, consistently driving cutting-edge medical efficiencies, innovation, and enhanced patient outcomes. For instance, pharmaceutical companies are seen embracing the implementation of telemedicine, collaborating with global telehealth services to offer both HCPs and medical professionals the ability to provide seamless remote patient consultations and support. One of the best benefits of telemedicine is the fact that it helps optimize patient accessibility to immediate quality medical professionals along with enhancing the efficacy and effectiveness of clinical trials (both monitoring and recruitment). 

In addition, pharma companies are also implementing state-of-the-art digital marketing strategies to creatively and effectively collaborate with HCPs, investors, and patients. For example, companies use digital marketing to effectively offer resonating and customized content delivery on various social media platforms and online communities, helping educate medical professionals, MSLs, stakeholders, and patients. Moreover, regulatory authorities have also accepted and implemented the use of digital technologies to make their regulatory submissions ever more efficient, which is highly advantageous for pharmaceuticals to get rapid approvals. 

Sustainability and Green Initiatives

After the brunt of the COVID-19 pandemic, there was a quick and positive tilt towards implementing sustainable workplace initiatives, the chief amongst them being working from home. Medical manufacturers, pharmaceuticals, and several other industries are motivating their workforce to work remotely. 

Companies such as MphaR were able to develop a wide variety of state-of-the-art virtual platforms that are now used by global pharmaceuticals to significantly reduce their carbon footprint in a strive for achieving net zero emissions. MphaR's green initiative, the company designed digital tools and platforms to help HCPs, KOLs, stakeholders, and pharmaceuticals to effectively collaborate with one another to gather key medical insights and information from a slew of global experts. MphaR's virtual environment plays an instrumental role in bringing top-notch medical professionals and pharma manufacturers together in a seamless and divergent effort to streamline clinical trials and develop new drugs and innovative medical strategies for better patient care and outcomes. 

The company's digital ecosystem offers a more diverse and technology-centric approach to maximize process efficiencies while operating more sustainably. For instance, MphaR's Green Initiative has helped significantly reduce the need for key opinion leaders, pharma representatives, and other stakeholders from having to travel to attend though-leading conferences. Their virtual advisory board boasts a sustainable and completely digital alternative for HCPs and other professionals to organize seamless interactions and engagement no matter where they are in the world. 

Bottom Line

In all, there's no question that the modern pharmaceutical industry is experiencing a rapid and fruitful digital transformation propelled by innovative and future-proof advancements, dynamically modifying healthcare while introducing cutting-edge approaches for favorable patient outcomes.

Subscribe to our Medical Affairs Digest

Join thousands of experts who already enjoy our newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.